{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:23:42Z","timestamp":1791329022234,"version":"4.3.1"},"reference-count":58,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100012168","name":"Spark Program","doi-asserted-by":"crossref","award":["No. XHJH-0048"],"award-info":[{"award-number":["No. XHJH-0048"]}],"id":[{"id":"10.13039\/501100012168","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Qian Dong Nan Science and Technology Program","award":["No. qdnkhJz [2023] 14"],"award-info":[{"award-number":["No. qdnkhJz [2023] 14"]}]},{"name":"Scientific Research Project of Guizhou Provincial Health and Wellness Commission","award":["No. gzwkj 2024-099"],"award-info":[{"award-number":["No. gzwkj 2024-099"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technol Cancer Res Treat"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop and validate a CT-based radiomics model for predicting sequential immunotherapy response after concurrent radiochemotherapy (CCRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study retrospectively included 71 patients who received sequential immunotherapy after concurrent chemoradiotherapy (CCRT) between January 2019 and December 2022, while prospectively including 17 additional patients between January 2023 and July 2023. The study documented each patient's tumor response and prognosis within two months of completing treatment. Patients were then categorized based on their treatment response, resulting in the identification of two distinct groups: treatment-responsive group and treatment-insensitive group. First, ITK-SNAP software was used to delineate the primary tumor lesions in the lung window and define a region of interest (ROI). Second, features were extracted using Python (version 3.6) and filtered using Least absolute shrinkage and selection operator regression. Third, radiological models were built using six machine learning algorithms: logistic regression (LR), discriminant analysis (DA), neural network (NN), random forest (RF), support vector machine (SVM) and K-Nearest Neighbour (KNN). Finally, Kaplan-Meier survival analysis was performed for high- and low-risk patients predicted by radiomic modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Based on the performance of radiomics models constructed by various machine learning algorithms in the prospective validation set, the LR with the highest AUC value (AUC: 90.00%) was finally selected, which also performed well in the independent test set (AUC: 84.96%). Risk stratification of patients based on the radiomic model constructed by LR was excellent for PFS (P\u2009=\u20090.001) and OS (P\u2009=\u20090.019) in the training set, PFS (P\u2009=\u20090.010) and OS (P\u2009=\u20090.028) in the prospective validation set, and PFS (P\u2009=\u20090.014) and OS (P\u2009=\u20090.041) in the test set.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Pretreatment CT-based radiomics model accurately and efficiently predicts treatment response and risk stratification in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy and sequential programmed death-1 inhibitor therapy. Prior to prospective data collection, the study was registered with the China Clinical Trial Registry under the trial registration name: Prediction of concurrent chemoradiotherapy efficacy and its related molecular signaling pathway by medical artificial intelligence model based on CT of lung cancer, with the registration number: ChiCTR2100053175 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.chictr.org.cn\/showproj.html?proj\">https:\/\/www.chictr.org.cn\/showproj.html?proj<\/jats:ext-link>\n                      \u2009\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/=\">=<\/jats:ext-link>\n                      \u2009\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/136872\">136872<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/15330338251351109","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T03:48:20Z","timestamp":1749700100000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Pretreatment CT-Based Machine Learning Radiomics Model Predicts Response in Inoperable Stage III NSCLC Treated with Concurrent Radiochemotherapy Plus PD-1 Inhibitors"],"prefix":"10.1177","volume":"24","author":[{"given":"Ya","family":"Li","sequence":"first","affiliation":[{"name":"The Second Affiliated Hospital of Guizhou Medical University"},{"name":"Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, China"},{"name":"Department of Oncology, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China"},{"name":"School of Clinical Medicine, Guizhou Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guizhou Medical University"},{"name":"Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, China"},{"name":"Department of Oncology, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China"},{"name":"School of Clinical Medicine, Guizhou Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guiyang Pulmonary Hospital, Guiyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guiyang Pulmonary Hospital, Guiyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youlong","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Guiyang Pulmonary Hospital, Guiyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianchu","family":"He","sequence":"additional","affiliation":[{"name":"Department of Oncology, Qiandongnan Prefecture People's Hospital, Kaili, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingdan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Qiannan Prefecture Hospital of Traditional Chinese Medicine, Duyun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benlan","family":"Li","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guizhou Medical University"},{"name":"Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, China"},{"name":"Department of Oncology, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China"},{"name":"School of Clinical Medicine, Guizhou Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Xia","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guizhou Medical University"},{"name":"Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, China"},{"name":"Department of Oncology, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China"},{"name":"School of Clinical Medicine, Guizhou Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjun","family":"Huang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guizhou Medical University"},{"name":"Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, China"},{"name":"Department of Oncology, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China"},{"name":"School of Clinical Medicine, Guizhou Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyang","family":"Lu","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guizhou Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Huang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guizhou Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, China"},{"name":"Department of Oncology, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China"},{"name":"School of Clinical Medicine, Guizhou Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8907-701X","authenticated-orcid":false,"given":"Jie","family":"Peng","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Guizhou Medical University"},{"name":"Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, China"},{"name":"Department of Oncology, Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China"},{"name":"School of Clinical Medicine, Guizhou Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.5334\/aogh.2419"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0882-3"},{"issue":"0","key":"e_1_3_4_5_2","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus PE","year":"2017","unstructured":"Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(0):iv1-iv21. DOI:https:\/\/doi.org\/10.1093\/annonc\/mdx222","journal-title":"Ann Oncol."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr325"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2543"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.09.009"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00630-6"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0013"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-04904-6"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.853254"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21552"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00742-2"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009348"},{"issue":"7","key":"e_1_3_4_19_2","article-title":"Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: A retrospective study","volume":"5","author":"Saad MB","year":"2023","unstructured":"Saad MB, Hong L, Aminu M, et al. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: A retrospective study. Lancet Digit Health. 2023;5(7):e404-e420. DOI:https:\/\/doi.org\/10.1016\/S2589-7500(23)00082-1","journal-title":"Lancet Digit Health"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.7150\/thno.48027"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.02.002"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2495"},{"issue":"0","key":"e_1_3_4_23_2","first-page":"175883592110687","article-title":"Predicting treatment outcomes using 18F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy","volume":"14","author":"Kim CG","year":"2022","unstructured":"Kim CG, Hwang SH, Kim KH, et al. Predicting treatment outcomes using 18F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy. Ther Adv Med Oncol. 2022;14(0):17588359211068732. DOI:https:\/\/doi.org\/10.1177\/17588359211068732","journal-title":"Ther Adv Med Oncol."},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0659"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0020"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2022.03.03"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.1253"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991431"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canrad.2011.04.003"},{"issue":"07","key":"e_1_3_4_31_2","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"350","author":"Gary SC","year":"2015","unstructured":"Gary SC, Johannes BR, Douglas GA, Karel GMM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350(jan07 4):g7594-g7594. DOI:https:\/\/doi.org\/10.1136\/bmj.g7594","journal-title":"BMJ"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1590\/0100-3984.2014.0012"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01162"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01164-5"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29371"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050915"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142608"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1074477"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature21724"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96582"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2015151169"},{"issue":"3","key":"e_1_3_4_42_2","article-title":"The future of radiomics in lung cancer","volume":"2","author":"Thawani R","year":"2020","unstructured":"Thawani R, Mustafa SA. The future of radiomics in lung cancer. Lancet Digit Health. 2020;2(3):e103. DOI:https:\/\/doi.org\/10.1016\/S2589-7500(20)30022-4","journal-title":"Lancet Digit Health"},{"issue":"0","key":"e_1_3_4_43_2","article-title":"5MO Prospective validation of a radiomics signature for chemoradiotherapy lung cancer patients","volume":"31","author":"Leijenaar R","year":"2020","unstructured":"Leijenaar R, Zerka F, Vaidyanathan A, et al. 5MO Prospective validation of a radiomics signature for chemoradiotherapy lung cancer patients. Ann Oncol. 2020;31(0):S246. DOI:https:\/\/doi.org\/10.1016\/j.annonc.2020.08.158","journal-title":"Ann Oncol."},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30391-X"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-024-01787-5"},{"issue":"0","key":"e_1_3_4_46_2","article-title":"178P Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients","volume":"34","author":"Provenzano L","year":"2023","unstructured":"Provenzano L, Favali M, Mazzeo L, et al. 178P Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients. Ann Oncol. 2023;34(0):S252. DOI:https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2902","journal-title":"Ann Oncol."},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03565-7"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-023-02755-3"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00363-7"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009355"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1129989"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1147903"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.17691\/stm2021.13.2.11"},{"issue":"0","key":"e_1_3_4_54_2","first-page":"1","article-title":"Prediction of CD3 T cells and CD8 T cells expression levels in non-small cell lung cancer based on radiomic features of CT images","volume":"13","author":"Lujiao C","year":"2023","unstructured":"Lujiao C, Lulin C, Hongxia N, et al. Prediction of CD3 T cells and CD8 T cells expression levels in non-small cell lung cancer based on radiomic features of CT images. Front Oncol. 2023;13(0):1-1. DOI:https:\/\/doi.org\/10.3389\/fonc.2023.1104316","journal-title":"Front Oncol."},{"issue":"8","key":"e_1_3_4_55_2","first-page":"4616","article-title":"Motility dynamics of T cells in tumor-draining lymph nodes: A rational indicator of antitumor response and immune checkpoint blockade","volume":"13","author":"Yasuhiro K","year":"2021","unstructured":"Yasuhiro K, Taku O, Tomoya K. Motility dynamics of T cells in tumor-draining lymph nodes: A rational indicator of antitumor response and immune checkpoint blockade. Cancers (Basel). 2021;13(8):4616-4616. DOI:https:\/\/doi.org\/10.3390\/cancers13184616","journal-title":"Cancers (Basel)."},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00303-x"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1047"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00932-9"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.01.016"}],"container-title":["Technology in Cancer Research &amp; Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338251351109","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15330338251351109","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15330338251351109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:16:42Z","timestamp":1777702602000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15330338251351109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":58,"alternative-id":["10.1177\/15330338251351109"],"URL":"https:\/\/doi.org\/10.1177\/15330338251351109","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/15330338251351109\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251351109\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251351109\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251351109\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251351109\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251351109\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/15330338251351109\/v2\/review2","asserted-by":"object"}]},"ISSN":["1533-0346","1533-0338"],"issn-type":[{"value":"1533-0346","type":"print"},{"value":"1533-0338","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"15330338251351109"}}